WHWK insider transaction filings
Whitehawk Therapeutics, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-09-18. Screen WHWK transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 12 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 23.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| BALL BRYAN — See remarks | 2 | — | — | 4 |
| Dornan David — Chief Scientific Officer | 2 | — | — | 4 |
| Dugan Margaret — Chief Medical Officer | 2 | — | — | 4 |
| Giacobello Scott M. — CHIEF FINANCIAL OFFICER | 2 | — | — | 4 |
| Lennon David James — CHIEF EXECUTIVE OFFICER, Director | 2 | — | — | 4 |
| Dalal Anupam — Director | 1 | — | — | 2 |
| Iyengar Vijay K — Director | 1 | — | — | 1 |
Recent Form 4 filings — Whitehawk Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-18 | 4/A | Dornan David — Chief Scientific Officer | Grant/award (A): 85,887 (derivative) @ $0 · Grant/award (A): 85,887 (derivative) @ $0 | EDGAR |
| 2026-09-18 | 4/A | BALL BRYAN — See remarks | Grant/award (A): 91,633 (derivative) @ $0 · Grant/award (A): 91,633 (derivative) @ $0 | EDGAR |
| 2026-09-18 | 4/A | Giacobello Scott M. — CHIEF FINANCIAL OFFICER | Grant/award (A): 118,476 (derivative) @ $0 · Grant/award (A): 118,476 (derivative) @ $0 | EDGAR |
| 2026-09-18 | 4/A | Dugan Margaret — Chief Medical Officer | Grant/award (A): 81,250 (derivative) @ $0 · Grant/award (A): 81,250 (derivative) @ $0 | EDGAR |
| 2026-09-18 | 4/A | Lennon David James — CHIEF EXECUTIVE OFFICER, Director | Grant/award (A): 193,957 (derivative) @ $0 · Grant/award (A): 193,957 (derivative) @ $0 | EDGAR |
| 2026-09-15 | 4 | BALL BRYAN — See remarks | Grant/award (A): 91,633 (derivative) @ $0 · Grant/award (A): 91,633 (derivative) @ $0 | EDGAR |
| 2026-09-15 | 4 | Dornan David — Chief Scientific Officer | Grant/award (A): 85,887 (derivative) @ $0 · Grant/award (A): 85,887 (derivative) @ $0 | EDGAR |
| 2026-09-15 | 4 | Dugan Margaret — Chief Medical Officer | Grant/award (A): 81,250 (derivative) @ $0 · Grant/award (A): 81,250 (derivative) @ $0 | EDGAR |
| 2026-09-15 | 4 | Giacobello Scott M. — CHIEF FINANCIAL OFFICER | Grant/award (A): 118,476 (derivative) @ $0 · Grant/award (A): 118,476 (derivative) @ $0 | EDGAR |
| 2026-09-15 | 4 | Lennon David James — CHIEF EXECUTIVE OFFICER, Director | Grant/award (A): 193,957 (derivative) @ $0 · Grant/award (A): 193,957 (derivative) @ $0 | EDGAR |
| 2026-09-11 | 4 | Iyengar Vijay K — Director | Grant/award (A): 76,080 (derivative) @ $0 | EDGAR |
| 2026-07-30 | 4 | Dalal Anupam — Director | Grant/award (A): 1,275,510 @ $3.92 · Grant/award (A): 38,040 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | Zhao Baiteng — Director | Grant/award (A): 38,040 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | Desai Neil — Director | Grant/award (A): 38,040 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | Aghazadeh Behzad — Director, 10% owner Avoro Capital Advisors LLC — Director, 10% owner Avoro Ventures LLC — Director, 10% owner | Grant/award (A): 38,040 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | Reeve Emma — Director | Grant/award (A): 38,040 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | Hirmand Mohammad — Director | Grant/award (A): 38,040 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | Maroun Richard E — Director | Grant/award (A): 38,040 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | Castelein Caley — Director | Grant/award (A): 38,040 (derivative) @ $0 | EDGAR |
| 2026-05-18 | 4 | Lennon David James — CHIEF EXECUTIVE OFFICER, Director | Grant/award (A): 51,021 @ $3.92 | EDGAR |
| 2026-05-18 | 4 | Dugan Margaret — Chief Medical Officer | Grant/award (A): 19,132 @ $3.92 | EDGAR |
| 2026-05-18 | 4 | BALL BRYAN — See remarks | Grant/award (A): 51,020 @ $3.92 | EDGAR |
| 2026-05-18 | 4 | Giacobello Scott M. — CHIEF FINANCIAL OFFICER | Grant/award (A): 38,265 @ $3.92 | EDGAR |
| 2026-05-18 | 4 | Castelein Caley — Director | Grant/award (A): 255,102 @ $3.92 · Grant/award (A): 2,072,756 (derivative) @ $8,124,996.24 | EDGAR |
| 2026-05-14 | 4 | Avoro Capital Advisors LLC — Director, 10% owner Aghazadeh Behzad — Director, 10% owner Avoro Ventures LLC — Director, 10% owner | Grant/award (A): 6,377,714 (derivative) @ $3.92 | EDGAR |
| 2026-04-17 | 4 | Giacobello Scott M. — CHIEF FINANCIAL OFFICER | Sale (S): 77,000 @ $3.86 · Sale (S): 141,600 @ $4.13 | EDGAR |
| 2026-04-15 | 4 | BALL BRYAN — See remarks | Sale (S): 26,389 @ $3.46 · Sale (S): 92,460 @ $3.64 | EDGAR |
| 2026-04-13 | 4 | BALL BRYAN — See remarks | Sale (S): 50,000 @ $3.57 · Sale (S): 6,596 @ $3.43 | EDGAR |
| 2026-04-10 | 4 | Lennon David James — CHIEF EXECUTIVE OFFICER, Director | Sale (S): 14,500 @ $3.38 | EDGAR |
| 2026-04-08 | 4 | Lennon David James — CHIEF EXECUTIVE OFFICER, Director | Sale (S): 102,395 @ $3.51 · Sale (S): 94,087 @ $3.43 · Sale (S): 63,945 @ $3.40 | EDGAR |
| 2026-04-03 | 4 | Lennon David James — CHIEF EXECUTIVE OFFICER, Director | Option exercise (M): 775,828 · Sale (S): 26,858 @ $3.48 · Option exercise (M): 775,828 (derivative) @ $0 · Grant/award (A): 831,148 (derivative) @ $0 | EDGAR |
| 2026-04-03 | 4 | Dugan Margaret — Chief Medical Officer | Grant/award (A): 283,157 (derivative) @ $0 | EDGAR |
| 2026-04-03 | 4 | Dornan David — Chief Scientific Officer | Grant/award (A): 282,340 (derivative) @ $0 | EDGAR |
| 2026-04-03 | 4 | BALL BRYAN — See remarks | Option exercise (M): 366,532 · Option exercise (M): 366,532 (derivative) @ $0 · Grant/award (A): 250,058 (derivative) @ $0 | EDGAR |
| 2026-04-03 | 4 | Giacobello Scott M. — CHIEF FINANCIAL OFFICER | Option exercise (M): 473,902 · Option exercise (M): 473,902 (derivative) @ $0 · Grant/award (A): 300,677 (derivative) @ $0 | EDGAR |
| 2026-03-10 | 4 | Lennon David James — CHIEF EXECUTIVE OFFICER, Director | Option exercise (M): 16,250 · Sale (S): 5,100 @ $3.31 · Option exercise (M): 16,250 (derivative) @ $0 | EDGAR |
| 2026-03-10 | 4 | BALL BRYAN — See remarks | Option exercise (M): 5,000 · Sale (S): 1,834 @ $3.31 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2026-03-10 | 4 | Giacobello Scott M. — CHIEF FINANCIAL OFFICER | Option exercise (M): 6,750 · Sale (S): 2,594 @ $3.31 · Option exercise (M): 6,750 (derivative) @ $0 | EDGAR |
| 2025-12-02 | 4 | Dugan Margaret — Chief Medical Officer | Grant/award (A): 650,000 (derivative) @ $0 · Grant/award (A): 55,309 (derivative) @ $0 | EDGAR |
| 2025-06-17 | 4 | Zhao Baiteng — Director | Grant/award (A): 40,006 (derivative) @ $0 | EDGAR |
| 2025-06-17 | 4 | Desai Neil — Director | Grant/award (A): 40,006 (derivative) @ $0 | EDGAR |
| 2025-06-16 | 4 | Hirmand Mohammad — Director | Grant/award (A): 40,006 (derivative) @ $0 | EDGAR |
| 2025-06-16 | 4 | Reeve Emma — Director | Grant/award (A): 40,006 (derivative) @ $0 | EDGAR |
| 2025-06-16 | 4 | Dalal Anupam — Director | Grant/award (A): 40,006 (derivative) @ $0 | EDGAR |
| 2025-06-16 | 4 | Aghazadeh Behzad — Director, 10% owner Avoro Capital Advisors LLC — Director, 10% owner Avoro Ventures LLC — Director, 10% owner | Grant/award (A): 40,006 (derivative) @ $0 | EDGAR |
| 2025-06-16 | 4 | Maroun Richard E — Director | Grant/award (A): 40,006 (derivative) @ $0 | EDGAR |
| 2025-06-16 | 4 | Castelein Caley — Director | Grant/award (A): 40,006 (derivative) @ $0 | EDGAR |
| 2025-04-03 | 4 | BALL BRYAN — See remarks | Grant/award (A): 366,532 (derivative) @ $0 · Grant/award (A): 366,532 (derivative) @ $0 | EDGAR |
| 2025-04-03 | 4 | Giacobello Scott M. — CHIEF FINANCIAL OFFICER | Grant/award (A): 473,902 (derivative) @ $0 · Grant/award (A): 473,902 (derivative) @ $0 | EDGAR |
| 2025-04-03 | 4 | Lennon David James — CHIEF EXECUTIVE OFFICER, Director | Grant/award (A): 775,828 (derivative) @ $0 · Grant/award (A): 775,828 (derivative) @ $0 | EDGAR |
Recent 8-K events — Whitehawk Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-10 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-12 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-21 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-13 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-06-13 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=WHWK returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →